Home › Funds › Avanza Fonder AB › ABT
Avanza Fonder AB position in ABT
ABBOTT LABORATORIES · Health Care
Avanza Fonder AB reported holding 211,093 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$20.9M, representing 0.40% of its reported portfolio and ranking #41 among its reported holdings. Avanza Fonder AB has disclosed ABT holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR
How Avanza Fonder AB's ABT position evolved
Avanza Fonder AB first disclosed a stake in ABT in Q4 2024 at 182,445 shares (US$20.6M). The position peaked in Q4 2025 at 195,451 shares, worth US$24.5M. Across 8 filings, Avanza Fonder AB increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 211,093 shares valued at US$20.9M — an increase of 22,234 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 182.44K | $20.64M | New |
| Q1 2025 | 167.75K | $22.13M | Reduce |
| Q2 2025 | 168.40K | $22.90M | Hold |
| Q3 2025 | 179.29K | $24.01M | Add |
| Q4 2025 | 195.45K | $24.49M | Add |
| Q1 2026 | 194.85K | $20.01M | Hold |
| Q2 2026 | 188.86K | $17.14M | Reduce |
| Q3 2026 | 211.09K | $20.86M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on Avanza Fonder AB
FAQ
How long has Avanza Fonder AB held ABT?
Avanza Fonder AB has disclosed ABT holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Avanza Fonder AB's current position in ABT?
As of Q3 2026, Avanza Fonder AB holds 211.09K shares of ABT (ABBOTT LABORATORIES), valued at $20.86M, representing 0.40% of its reported portfolio and ranking #41.
Has Avanza Fonder AB been buying or selling ABT?
In the latest 13F filing (Q3 2026), Avanza Fonder AB increased its position in ABT. The position peaked in Q4 2025 at 195.45K shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.